FDA Panel Gives Blessing To Merck & Co., Inc.'s Ragweed Allergy Pill

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Merck & Co's experimental drug Ragwitek, a treatment for ragweed allergies, appears safe and effective for use in patients between the ages of 18 and 65, a panel of advisors to the U.S. Food and Drug Administration concluded on Tuesday. The panel voted 6 to 2, with one abstention, that data supported the drug's efficacy. It voted 8 to 0, with one abstention, that the data supported the drug's safety.

Help employers find you! Check out all the jobs and post your resume.

Back to news